By Denny Jacob
Halozyme Therapeutics said it was ending an effort to acquire German drug developer Evotec.
Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage with the company on a potential deal, leading the biopharmaceutical company to withdraw its proposal.
San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Evotec would go on to confirm the takeover offer.
Shares of Halozyme jumped 12% to $51.32 in premarket trading Friday, while American depositary receipts of Evotec tumbled 14% to $4.60.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 22, 2024 09:07 ET (14:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.